CR-CHOP+X in Previously Untreated DEL

Abroad (travel likely)RecruitingPHASE2

Conditions

DLBCL

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Li Wang) · dr_wangli@126.com · 18917762217

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

Diffuse Large B-Cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE2

Suzhou, China

CAR-T Followed by Bispecific Antibodies

Large B-cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Omaha, United States · Philadelphia, United States

Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes

Diffuse Large B-Cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE2

Nanjing, China

Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma

DLBCL · CLL · FL

Abroad (travel likely)RecruitingPHASE1, PHASE2

Tianjin, China